NCT05481476View on ClinicalTrials.gov

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Pancreatic Neoplasms
Interventions
DRUG

Surufatinib

250mg, qd, po, 21 days for a cycle

DRUG

Sintilimab

200mg, ivgtt, d1, 21 days for a cycle, up to 2 years

DRUG

AG

nab-paclitaxel (125mg/ m2, ivgtt, d1, 8), Gemcitabine (1000mg/ m2, intravenous infusion over 30min, d1, 8), 21 days for a cycle, up to 6 cycles

Trial Locations (1)

510060

Cancer center of SunYat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER